Effect of platelet activating factor antagonist (CV-3988) on 6-keto-PGF1 alpha and thromboxane B2 in dogs with experimental endotoxin-induced shock.
The effect of CV-3988, a platelet activating factor antagonist, in the treatment of endotoxic shock was evaluated from the changes in plasma 6-keto-PGF1 alpha and thromboxane B2 concentrations. The animals consisted of 10 beagle dogs anesthetized with pentobarbital sodium and divided into a treatment group (n = 5) and a control group (n = 5). Endotoxic shock was experimentally induced in both groups by intravenous administration of endotoxin (lipopolysaccharide, 3 mg/kg). The treatment group was intravenously given 10 mg/kg of CV-3988 for 10 min from immediately after endotoxin. Mean aortic pressure, cardiac output and urine volume were remarkably decreased after the administration of endotoxin to both groups. These parameters were higher after the administration of CV-3988, in the treatment group than in the control group. Furthermore, the increase in plasma 6-keto-PGF1 alpha and thromboxane B2 concentrations was significantly inhibited. These results suggest the effectiveness of CV-3988 in the treatment of endotoxic shock.
Okano
S
S
Division of Veterinary Surgery, Nippon Veterinary and Animal Science University, Tokyo, Japan.
Tagawa
M
M
Urakawa
N
N
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D000818:Animals; D004283:Dog Diseases / Q000503:physiopathology*; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects; D010742:Phospholipid Ethers / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D012772:Shock, Septic / Q000503:physiopathology / Q000662:veterinary*; D013929:Thromboxane B2 / Q000097:blood*
D010742:Phospholipid Ethers; D010972:Platelet Activating Factor; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C037913:CV 3988